Deciphering PI3K biology in health and disease

Informazioni relative al progetto

Phd

ID dell’accordo di sovvenzione: 675392

DOI 10.3030/675392

Progetto chiuso

Data della firma CE 7 Agosto 2015

Data di avvio 1 Novembre 2015

Data di completamento 31 Ottobre 2019

Finanziato da

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Costo totale € 3 896 148,12

Contributo UE € 3 896 148,12

Coordinato da

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
Spain

Risultati finali

Other (6)

Research Training Workshop 2

Research Training Workshop

Research Training Workshop 3

Research Training Workshop

Recruitment
Research Training Workshop 4

Research Training Workshop

PhD Completion

Phd Completion

Research Training Workshop 1

Research Training Workshop

Documents, reports (5)

Dissemination and Outreach Plan 1

Dissemination and Outreach Plan

Dissemination and Outreach Plan 2

Dissemination and Outreach Plan

Dissemination and Outreach Plan 3

Dissemination and Outreach Plan

Mid-term review meeting

Meeting with fellows, members of consortium and REA representative to assess the work progress and achievements

Dissemination and Outreach Plan 4

Dissemination and Outreach Plan

Websites, patent fillings, videos etc. (2)

Network Website
Promotional Video

Pubblicazioni

Peer reviewed articles (5)

Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility

Autori: Ana Angulo-Urarte, Pedro Casado, Sandra D. Castillo, Piotr Kobialka, Maria Paraskevi Kotini, Ana M. Figueiredo, Pau Castel, Vinothini Rajeeve, Maria Milà-Guasch, Jaime Millan, Cora Wiesner, Helena Serra, Laia Muixi, Oriol Casanovas, Francesc Viñals, Markus Affolter, Holger Gerhardt, Stephan Huveneers, Heinz-Georg Belting, Pedro R. Cutillas, Mariona Graupera
Pubblicato in: Nature Communications, Numero 9/1, 2018, ISSN 2041-1723
Editore: Nature Publishing Group
DOI: 10.1038/s41467-018-07172-3

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Autori: Florent Beaufils, Natasa Cmiljanovic, Vladimir Cmiljanovic, Thomas Bohnacker, Anna Melone, Romina Marone, Eileen Jackson, Xuxiao Zhang, Alexander Sele, Chiara Borsari, Jürgen Mestan, Paul Hebeisen, Petra Hillmann, Bernd Giese, Marketa Zvelebil, Doriano Fabbro, Roger L. Williams, Denise Rageot, Matthias P. Wymann
Pubblicato in: Journal of Medicinal Chemistry, Numero 60/17, 2017, Pagina/e 7524-7538, ISSN 0022-2623
Editore: American Chemical Society
DOI: 10.1021/acs.jmedchem.7b00930

The role of metabolic adaptation to nutrient stress in pancreatic cancer

Autori: Abhishek Derle, Maria Chiara De Santis, Luca Gozzelino, Edoardo Ratto, Miriam Martini
Pubblicato in: Cell Stress, Numero 2/12, 2018, Pagina/e 332-339, ISSN 2523-0204
Editore: Shared Science Publishers
DOI: 10.15698/cst2018.12.166

Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics

Autori: Célia Cintas, Thibaut Douché, Nicole Therville, Silvia Arcucci, Fernanda Ramos-Delgado, Céline Basset, Benoît Thibault, Julie Guillermet-Guibert
Pubblicato in: Cancers, Numero 10/6, 2018, Pagina/e 174, ISSN 2072-6694
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers10060174

Experimental pancreatic cancer develops in soft pancreas: novel leads for an individualized diagnosis by ultrafast elasticity imaging

Autori: Nicole Therville, Silvia Arcucci, Aurélie Vertut, Fernanda Ramos-Delgado, Dina Ferreira Da Mota, Marlène Dufresne, Céline Basset, Julie Guillermet-Guibert
Pubblicato in: Theranostics, Numero 9/22, 2019, Pagina/e 6369-6379, ISSN 1838-7640
Editore: Ivyspring International Publisher
DOI: 10.7150/thno.34066